ebastine
E850018
H1 receptor antagonist
non-sedating antihistamine
pharmaceutical drug
second-generation antihistamine
Ebastine is a second-generation, non-sedating antihistamine used primarily to treat allergic rhinitis and chronic urticaria.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Ebastine | 0 |
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
H1 receptor antagonist
ⓘ
non-sedating antihistamine ⓘ pharmaceutical drug ⓘ second-generation antihistamine ⓘ |
| actsOn | histamine H1 receptor ⓘ |
| belongsToClass | piperidine antihistamines ⓘ |
| discoveredAs | second-generation derivative of first-generation antihistamines ⓘ |
| eliminationHalfLife | long half-life of active metabolite carebastine ⓘ |
| hasActiveMetabolite | carebastine NERFINISHED ⓘ |
| hasAdministrationAdvice | can be taken with or without food ⓘ |
| hasATCCode | R06AX22 ⓘ |
| hasContraindication | hypersensitivity to ebastine ⓘ |
| hasDosageForm |
oral suspension
ⓘ
tablet ⓘ |
| hasDrugInteraction |
CYP3A4 inhibitors
ⓘ
erythromycin NERFINISHED ⓘ ketoconazole NERFINISHED ⓘ |
| hasDurationOfEffect | approximately 24 hours ⓘ |
| hasOnsetOfAction | within a few hours after oral administration ⓘ |
| hasPharmacologicalEffect |
anti-allergic effect
ⓘ
antihistaminic effect ⓘ reduction of nasal symptoms ⓘ reduction of pruritus ⓘ reduction of wheal and flare response ⓘ |
| hasProperty |
long duration of action
ⓘ
low sedative potential ⓘ minimal central nervous system penetration ⓘ once-daily dosing ⓘ |
| hasRegulatoryApproval | approved in various European and Asian countries ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSideEffect |
dizziness
ⓘ
dry mouth ⓘ headache ⓘ somnolence ⓘ |
| hasStandardDose |
10 mg once daily for allergic rhinitis in adults
ⓘ
10–20 mg once daily for chronic urticaria in adults ⓘ |
| hasTherapeuticUse |
allergic rhinitis
ⓘ
chronic urticaria ⓘ perennial allergic rhinitis ⓘ seasonal allergic rhinitis ⓘ |
| legalStatus | prescription-only medicine in many countries ⓘ |
| mayCause | QT interval prolongation in predisposed patients ⓘ |
| metabolism |
CYP3A4-mediated metabolism
ⓘ
hepatic metabolism ⓘ |
| pregnancyCategory | use with caution in pregnancy ⓘ |
| usedIn |
adult patients
ⓘ
pediatric patients above specific age thresholds ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.